CRP and COVID-19: In early clinical studies, tocilizumab significantly improved several outcomes in severe and critical COVID-19 cases, including supplemental oxygen utilization and C-reactive protein and D-dimer levels (Sciascia et al., 2020; Xu X. et al., 2020).